These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 31078412)

  • 1. High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC-MS, network Pharmacology, Docking, and molecular dynamics.
    Gao K; Chen Z; Zhang N; Jiang P
    Saudi Pharm J; 2024 Sep; 32(9):102139. PubMed ID: 39139718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of scaberol C amino acid ester derivatives with anti-cancer activity.
    Li CL; Han Z; Luo DY; Ren H; Ye L; Yao GD; Liu QB
    J Asian Nat Prod Res; 2024 Jul; ():1-18. PubMed ID: 39067002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.
    Singh PK; Pathania S; Rawal RK
    SAR QSAR Environ Res; 2020 Nov; 31(11):857-867. PubMed ID: 33100032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET.
    Singh PK; Silakari O
    Bioorg Chem; 2018 Sep; 79():163-170. PubMed ID: 29758406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
    Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
    Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
    Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
    Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
    Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC.
    Singh PK; Chaudhari D; Jain S; Silakari O
    Bioorg Med Chem Lett; 2019 Jul; 29(13):1565-1571. PubMed ID: 31078412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGFR
    Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
    Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
    Corallo S; D'Argento E; Strippoli A; Basso M; Monterisi S; Rossi S; Cassano A; Barone CM
    Target Oncol; 2017 Apr; 12(2):153-161. PubMed ID: 28188446
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.